JP2024123231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024123231A5 JP2024123231A5 JP2024103109A JP2024103109A JP2024123231A5 JP 2024123231 A5 JP2024123231 A5 JP 2024123231A5 JP 2024103109 A JP2024103109 A JP 2024103109A JP 2024103109 A JP2024103109 A JP 2024103109A JP 2024123231 A5 JP2024123231 A5 JP 2024123231A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- phenylalanine
- psma
- drug conjugate
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 9
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 5
- 108010059074 monomethylauristatin F Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 229960004441 tyrosine Drugs 0.000 claims 3
- DDLYNVBJVVOUGB-QMMMGPOBSA-N (2s)-2-amino-3-(3-aminophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(N)=C1 DDLYNVBJVVOUGB-QMMMGPOBSA-N 0.000 claims 2
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 229930188854 dolastatin Natural products 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940125697 hormonal agent Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- OUGDEOOFDGWUAC-QMMMGPOBSA-N (2S)-2-amino-3-(3-sulfooxyphenyl)propanoic acid Chemical compound S(=O)(=O)(O)OC=1C=C(C[C@H](N)C(=O)O)C=CC1 OUGDEOOFDGWUAC-QMMMGPOBSA-N 0.000 claims 1
- YYTDJPUFAVPHQA-VKHMYHEASA-N (2s)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C(F)=C(F)C(F)=C1F YYTDJPUFAVPHQA-VKHMYHEASA-N 0.000 claims 1
- DJZAVKNBQZFEAL-QMMMGPOBSA-N (2s)-2-amino-3-(2-aminophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1N DJZAVKNBQZFEAL-QMMMGPOBSA-N 0.000 claims 1
- QTCRLZGTYUJQIE-ZETCQYMHSA-N (2s)-2-amino-3-(2-sulfooxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1OS(O)(=O)=O QTCRLZGTYUJQIE-ZETCQYMHSA-N 0.000 claims 1
- YDYSBABSIVBERF-ZETCQYMHSA-N (2s)-2-amino-3-(2-sulfophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1S(O)(=O)=O YDYSBABSIVBERF-ZETCQYMHSA-N 0.000 claims 1
- POGSZHUEECCEAP-ZETCQYMHSA-N (2s)-2-amino-3-(3-amino-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(N)=C1 POGSZHUEECCEAP-ZETCQYMHSA-N 0.000 claims 1
- SUPCVWGCSKIXFE-QMMMGPOBSA-N (2s)-2-amino-3-(3-sulfophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(S(O)(=O)=O)=C1 SUPCVWGCSKIXFE-QMMMGPOBSA-N 0.000 claims 1
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 claims 1
- OHQAEAFCFJFHEV-JAVCKPHESA-N (2s)-2-amino-3-(4-hydroxy-4-sulfocyclohexa-1,5-dien-1-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CCC(O)(S(O)(=O)=O)C=C1 OHQAEAFCFJFHEV-JAVCKPHESA-N 0.000 claims 1
- JSXMFBNJRFXRCX-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC#C)C=C1 JSXMFBNJRFXRCX-NSHDSACASA-N 0.000 claims 1
- BJOQKIKXKGJLIJ-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CC#C)C=C1 BJOQKIKXKGJLIJ-NSHDSACASA-N 0.000 claims 1
- ALQIUGWFHKQQHV-QMMMGPOBSA-N (2s)-2-amino-3-(4-sulfophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(S(O)(=O)=O)C=C1 ALQIUGWFHKQQHV-QMMMGPOBSA-N 0.000 claims 1
- SDZGVFSSLGTJAJ-ZETCQYMHSA-N (2s)-2-azaniumyl-3-(2-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1[N+]([O-])=O SDZGVFSSLGTJAJ-ZETCQYMHSA-N 0.000 claims 1
- YTHDRUZHNYKZGF-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(3-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=CC([N+]([O-])=O)=C1 YTHDRUZHNYKZGF-QMMMGPOBSA-N 0.000 claims 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 claims 1
- PQUSMXUQSMSWNN-QMMMGPOBSA-N (2s)-3-(2-amino-4-hydroxyphenyl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1N PQUSMXUQSMSWNN-QMMMGPOBSA-N 0.000 claims 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 claims 1
- SXIFEQOVCDBNET-QMMMGPOBSA-N 2-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1C(O)=O SXIFEQOVCDBNET-QMMMGPOBSA-N 0.000 claims 1
- JANONUPBHGWOBP-QMMMGPOBSA-N 3-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(C(O)=O)=C1 JANONUPBHGWOBP-QMMMGPOBSA-N 0.000 claims 1
- JZRBSTONIYRNRI-VIFPVBQESA-N 3-methylphenylalanine Chemical compound CC1=CC=CC(C[C@H](N)C(O)=O)=C1 JZRBSTONIYRNRI-VIFPVBQESA-N 0.000 claims 1
- IRZQDMYEJPNDEN-UHFFFAOYSA-N 3-phenyl-2-aminobutanoic acid Natural products OC(=O)C(N)C(C)C1=CC=CC=C1 IRZQDMYEJPNDEN-UHFFFAOYSA-N 0.000 claims 1
- YXDGRBPZVQPESQ-QMMMGPOBSA-N 4-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(O)=O)C=C1 YXDGRBPZVQPESQ-QMMMGPOBSA-N 0.000 claims 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 claims 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 claims 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 claims 1
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 claims 1
- 125000002355 alkine group Chemical group 0.000 claims 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229950006137 dexfosfoserine Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- TVIDEEHSOPHZBR-AWEZNQCLSA-N para-(benzoyl)-phenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 claims 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 claims 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide group Chemical group NNC(=O)N DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650277P | 2018-03-29 | 2018-03-29 | |
| US62/650,277 | 2018-03-29 | ||
| PCT/US2019/025057 WO2019191728A1 (en) | 2018-03-29 | 2019-03-29 | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
| JP2020551572A JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Division JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024123231A JP2024123231A (ja) | 2024-09-10 |
| JP2024123231A5 true JP2024123231A5 (https=) | 2025-03-11 |
Family
ID=66103056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Active JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
| JP2024103109A Pending JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Active JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12059473B2 (https=) |
| EP (2) | EP4461318A3 (https=) |
| JP (2) | JP7512202B2 (https=) |
| KR (2) | KR20250141858A (https=) |
| CN (2) | CN117924503A (https=) |
| AU (2) | AU2019245444B2 (https=) |
| BR (1) | BR112020019611A2 (https=) |
| CA (2) | CA3282900A1 (https=) |
| DK (1) | DK3773910T3 (https=) |
| ES (1) | ES2988767T3 (https=) |
| FI (1) | FI3773910T3 (https=) |
| HR (1) | HRP20241082T1 (https=) |
| HU (1) | HUE068337T2 (https=) |
| IL (2) | IL277357B2 (https=) |
| LT (1) | LT3773910T (https=) |
| MX (2) | MX2020010104A (https=) |
| PL (1) | PL3773910T3 (https=) |
| PT (1) | PT3773910T (https=) |
| RS (1) | RS66103B1 (https=) |
| SG (1) | SG11202009670RA (https=) |
| SI (1) | SI3773910T1 (https=) |
| SM (1) | SMT202400364T1 (https=) |
| WO (1) | WO2019191728A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021086917A1 (en) * | 2019-10-29 | 2021-05-06 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| US20230071763A1 (en) * | 2020-01-06 | 2023-03-09 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| EP4221763A4 (en) * | 2020-10-01 | 2025-11-12 | Univ Cornell | METHODS AND COMPOSITIONS FOR INCREASING THE ABSORPTION, INTERNALIZATION AND/OR RETENTION OF SMALL MOLECULE LIGANDS |
| US20230374150A1 (en) * | 2020-10-12 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| US20230390411A1 (en) * | 2021-01-28 | 2023-12-07 | Nanjing Chempion Biotechnology Co., Ltd. | Conjugate and use thereof |
| JP2025535713A (ja) | 2022-10-07 | 2025-10-28 | アンブレツクス・インコーポレイテツド | 薬物リンカー及びその抗体コンジュゲート |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| WO2024182569A2 (en) * | 2023-02-28 | 2024-09-06 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| AU2023448948A1 (en) * | 2023-05-24 | 2025-10-09 | Hangzhou Dac Biotech Co., Ltd | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate |
| TW202521545A (zh) * | 2023-08-04 | 2025-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｐｓｍａ抗體－藥物偶聯物及其醫藥用途 |
| IL326709A (en) * | 2023-08-22 | 2026-04-01 | Ambrx Inc | Anti-PSMA ADC conjugate compositions and methods of using them |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN118754934B (zh) * | 2024-06-05 | 2025-02-07 | 浙江新码生物医药有限公司 | 一种用于制备药物偶联物的毒素衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| AU2015203742B2 (en) | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| PT2318029T (pt) | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US10800856B2 (en) * | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| JP2015521602A (ja) * | 2012-06-14 | 2015-07-30 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 核受容体リガンドポリペプチドに対して複合化されている抗ｐｓｍａ抗体 |
| JP6584012B2 (ja) * | 2013-10-06 | 2019-10-02 | アメリカ合衆国 | 改変シュードモナス外毒素ａ |
| WO2017212250A1 (en) * | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| EP3630977B1 (en) | 2017-06-02 | 2024-02-21 | Ambrx, Inc. | Methods and compositions for promoting non-natural amino acid-containing protein production |
-
2019
- 2019-03-29 US US17/042,838 patent/US12059473B2/en active Active
- 2019-03-29 IL IL277357A patent/IL277357B2/en unknown
- 2019-03-29 MX MX2020010104A patent/MX2020010104A/es unknown
- 2019-03-29 BR BR112020019611-8A patent/BR112020019611A2/pt unknown
- 2019-03-29 PT PT197171739T patent/PT3773910T/pt unknown
- 2019-03-29 SI SI201930799T patent/SI3773910T1/sl unknown
- 2019-03-29 HR HRP20241082TT patent/HRP20241082T1/hr unknown
- 2019-03-29 PL PL19717173.9T patent/PL3773910T3/pl unknown
- 2019-03-29 FI FIEP19717173.9T patent/FI3773910T3/fi active
- 2019-03-29 WO PCT/US2019/025057 patent/WO2019191728A1/en not_active Ceased
- 2019-03-29 RS RS20241125A patent/RS66103B1/sr unknown
- 2019-03-29 SM SM20240364T patent/SMT202400364T1/it unknown
- 2019-03-29 CN CN202410093812.9A patent/CN117924503A/zh active Pending
- 2019-03-29 IL IL320375A patent/IL320375A/en unknown
- 2019-03-29 CA CA3282900A patent/CA3282900A1/en active Pending
- 2019-03-29 EP EP24190121.4A patent/EP4461318A3/en active Pending
- 2019-03-29 ES ES19717173T patent/ES2988767T3/es active Active
- 2019-03-29 CN CN201980025915.9A patent/CN111989138B/zh active Active
- 2019-03-29 JP JP2020551572A patent/JP7512202B2/ja active Active
- 2019-03-29 KR KR1020257031656A patent/KR20250141858A/ko active Pending
- 2019-03-29 AU AU2019245444A patent/AU2019245444B2/en active Active
- 2019-03-29 DK DK19717173.9T patent/DK3773910T3/da active
- 2019-03-29 CA CA3094985A patent/CA3094985C/en active Active
- 2019-03-29 LT LTEPPCT/US2019/025057T patent/LT3773910T/lt unknown
- 2019-03-29 HU HUE19717173A patent/HUE068337T2/hu unknown
- 2019-03-29 EP EP19717173.9A patent/EP3773910B1/en active Active
- 2019-03-29 SG SG11202009670RA patent/SG11202009670RA/en unknown
- 2019-03-29 KR KR1020207030091A patent/KR102864931B1/ko active Active
-
2020
- 2020-09-25 MX MX2024007724A patent/MX2024007724A/es unknown
-
2024
- 2024-06-26 JP JP2024103109A patent/JP2024123231A/ja active Pending
- 2024-07-01 US US18/761,130 patent/US20240350835A1/en active Pending
-
2025
- 2025-06-26 AU AU2025204809A patent/AU2025204809A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024123231A5 (https=) | ||
| IL317851A (en) | IL-15 conjugates and their use | |
| JP2021535140A5 (https=) | ||
| JP2020529977A5 (https=) | ||
| CN111163809B (zh) | 转谷氨酰胺酶缀合方法和接头 | |
| US6177404B1 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| JP2023082090A5 (https=) | ||
| US6391305B1 (en) | Conjugates useful in the treatment of prostate cancer | |
| JP2020529976A5 (https=) | ||
| Lenk et al. | Phase II clinical trial of high-dose recombinant human tumor necrosis factor | |
| AU726434B2 (en) | Conjugates useful in the treatment of prostate cancer | |
| HRP20240344T1 (hr) | Postupci i pripravci za unapređenje produkcije proteina koji sadrže neprirodne aminokiseline | |
| WO1997012624A1 (en) | Novel peptides | |
| CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
| HUP0300246A2 (en) | Delivery system | |
| EP0925308A2 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| CA2135787C (en) | Polypeptide bombesin antagonists | |
| AU726379B2 (en) | Recombinant ribonuclease proteins | |
| NO330913B1 (no) | Konjugeringsprodukt, dets anvendelse og farmasoytisk preparat inneholdende det samme. | |
| CA2232240C (en) | Peptide for inhibiting growth of smooth muscle cells | |
| EP0975762A1 (en) | Type-1 ribosome-inactivating protein | |
| JPWO2020047176A5 (https=) | ||
| US20020137684A1 (en) | Ligand for enhancing oral and CNS delivery of biological agents | |
| EP0855910A1 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| JPWO2020082057A5 (https=) |